Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: A SEER population-based study

Journal of Clinical Oncology

Volumn 31, Issue 7, 2013, Pages 930-937

  Solomon, Benjamin M ^a   Rabe, Kari G ^a   Slager, Susan L ^a   Brewer, Jerry D ^a   Cerhan, James R ^a   Shanafelt, Tait D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER REGISTRY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; COLORECTAL CANCER; FEMALE; HAZARD RATIO; HUMAN; KIDNEY CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LUNG NEOPLASMS; MALE; MIDDLE AGED; ODDS RATIO; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS; SEER PROGRAM; UNITED STATES;

EID: 84875712510     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.4449     Document Type: Article

References (32)

1. National Cancer Institute: Surveillance, Epidemiology, and End Results: Populations (1969-2010). http://seer.cancer.gov/.
2. Hisada M, Biggar RJ, Greene MH, et al: Solid tumors after chronic lymphocytic leukemia. Blood 98:1979-1981, 2001.
3. Manusow D, Weinerman BH: Subsequent neoplasia in chronic lymphocytic leukemia. JAMA 232:267-269, 1975.
4. Morton LM, Curtis RE, Linet MS, et al: Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: Differences by lymphoma subtype. J Clin Oncol 28:4935-4944, 2010.
5. Tsimberidou AM, Wen S, McLaughlin P, et al: Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol 27: 904-910, 2009.
6. Schöllkopf C, Rosendahl D, Rostgaard K, et al: Risk of second cancer after chronic lymphocytic leukemia. Int J Cancer 121:151-156, 2007.
7. Santoro A, Rilke F, Franchi F, et al: Primary malignant neoplasms associated with chronic lymphocytic leukemia. Tumori 66:431-437, 1980.
8. Royle JA, Baade PD, Joske D, et al: Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: A populationbased study. Br J Cancer 105:1076-1081, 2011.
9. Girschik J, Fritschi L, Threlfall T, et al: Deaths from non-melanoma skin cancer in Western Australia. Cancer Causes Control 19:879-885, 2008.
10. Hartley BE, Searle AE, Breach NM, et al: Aggressive cutaneous squamous cell carcinoma of the head and neck in patients with chronic lymphocytic leukaemia. J Laryngol Otol 110:694-695, 1996.
11. Wiernik PH: Second neoplasms in patients with chronic lymphocytic leukemia. Curr Treat Options Oncol 5:215-223, 2004.
12. Brewer JD, Shanafelt TD, Otley CC, et al: Chronic lymphocytic leukemia decreases survival of patients with malignant melanoma and merkel cell carcinoma in a SEER population-based study. J Clin Oncol 30:843-849, 2012.
13. Brewer JD, Christenson LJ, Weenig RH, et al: Effects of chronic lymphocytic leukemia on the development and progression of malignant melanoma. Dermatol Surg 36:368-376, 2010.
14. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62:10-29, 2012.
15. National Cancer Institute: Surveillance, Epidemiology, and End Results: SEER stat fact sheets-All sites. http://seer.cancer.gov/statfacts/html/all.html.
16. Therneau T, Grambsch P: Modeling Survival Data: Extending the Cox Model. New York, NY, Springer, 2000.
17. Aslakson CJ, Lee G, Boomer JS, et al: Expression of regeneration and tolerance factor on B cell chronic lymphocytic leukemias: A possible mechanism for escaping immune surveillance. Am J Hematol 61:46-52, 1999.
18. Cantwell M, Hua T, Pappas J, et al: Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat Med 3:984-989, 1997.
19. Francis S, Karanth M, Pratt G, et al: The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. Cancer 107:1023-1033, 2006.
20. Lacombe C, Gombert J, Dreyfus B, et al: Heterogeneity of serum IgG subclass deficiencies in B chronic lymphocytic leukemia. Clin Immunol 90: 128-132, 1999.
21. Morrison VA: Management of infectious complications in patients with chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 332-338, 2007.
22. Wadhwa PD, Morrison VA: Infectious complications of chronic lymphocytic leukemia. Semin Oncol 33:240-249, 2006.
23. US Preventive Services Task Force: Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 151:716-726, 2009.
24. US Preventive Services Task Force: Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 149:627-637, 2008.
25. Adjuvant! Online. http://www.adjuvantonline.com.
26. Grotz TE, Mansfield AS, Jakub JW, et al: Regional lymphatic immunity in melanoma. Melanoma Res 22:9-18, 2012.
27. Fishman M, Seigne J: Immunotherapy of metastatic renal cell cancer. Cancer Control 9:293-304, 2002.
28. Dores GM, Anderson WF, Curtis RE, et al: Chronic lymphocytic leukaemia and small lymphocytic lymphoma: Overview of the descriptive epidemiology. Br J Haematol 139:809-819, 2007.
29. Zent CS, Kyasa MJ, Evans R, et al: Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data. Cancer 92:1325-1330, 2001.
30. Damle RN, Wasil T, Fais F, et al: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840-1847, 1999.
31. Hamblin TJ, Davis Z, Gardiner A, et al: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848-1854, 1999.
32. Crespo M, Bosch F, Villamor N, et al: ZAP-70 expression as a surrogate for immunoglobulinvariable- region mutations in chronic lymphocytic leukemia. N Engl J Med 348:1764-1775, 2003.